Clinical Conversations (CE): GLP Practice Insights: GLP-1 Receptor Agonists and Neurodegenerative Disorders (CE)
This session discusses the potential sites of action and benefits for GLP-1 agonists (GLP-1a) in the pathology of two neurodegenerative disorders, Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). This session will also review the published and pending clinical literature of FDA approved GLP-1a use in AD and PD.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.